Date of Award


Document Type

Open Access Thesis

Degree Name

MS in Physician Assistant Studies (PA)


Physician Assistant Studies

First Advisor

Kristen Lindvall, PA-C


Idiopathic gastroparesis is a chronic symptomatic motility disorder of the stomach of unknown cause characterized by delayed gastric emptying in the absence of mechanical obstruction, with the majority of gastroparesis cases being classified as idiopathic. Idiopathic gastroparesis continues to be a challenging diagnosis to manage and difficulty remains in treating associated symptoms that result in decreased quality of life. Current non-invasive recommendations for the treatment of idiopathic gastroparesis are lifestyle modifications, including dietary adjustments to follow a gastroparesis diet, and pharmacotherapy prescribed for symptomatic relief. Metoclopramide is currently the only medication approved by the Food and Drug Administration (FDA) in the United States specifically for the indication of treating gastroparesis. Other medications are prescribed off-label for the indication of idiopathic gastroparesis or are prescribed to target specific symptoms. Response to treatment is both individualized and unpredictab􏰋e, a􏰇d 􏰈edica􏰁i􏰃􏰇􏰆􏰊 􏰆ide-effects may necessitate discontinuance. In the treatment of adults with idiopathic gastroparesis, it has been concluded that lifestylemodifications, pharmacotherapy, or both may improve, eliminate or fail to improve the symptoms of nausea, vomiting, early satiety, and poor appetite. Ultimately, risks and benefits of each option need to be discussed and shared decision-making needs to occur to establish a treatment regimen and management plan for patients with idiopathic gastroparesis.


SC 11.PAS.2020.Schieffer.R